Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:37:55 14/06/2024 BST 5-day change 1st Jan Change
40.86 USD -0.62% Intraday chart for Ionis Pharmaceuticals, Inc. +3.14% -18.72%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 598M 47.2B Sales 2025 * 767M 60.54B Capitalization 6B 473B
Net income 2024 * -573M -45.23B Net income 2025 * -520M -41.05B EV / Sales 2024 * 9.47 x
Net cash position 2024 * 335M 26.47B Net Debt 2025 * 72.35M 5.71B EV / Sales 2025 * 7.91 x
P/E ratio 2024 *
-10.8 x
P/E ratio 2025 *
-12.5 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.62%
1 week+3.14%
Current month+9.45%
1 month+5.98%
3 months-4.73%
6 months-16.30%
Current year-18.72%
More quotes
1 week
38.09
Extreme 38.09
41.80
1 month
35.95
Extreme 35.95
41.80
Current year
35.95
Extreme 35.95
54.44
1 year
35.95
Extreme 35.95
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 30/06/12
Founder 62 09/01/89
Director of Finance/CFO 62 30/04/00
Members of the board TitleAgeSince
Chairman 72 02/02/14
Founder 62 09/01/89
Director/Board Member 70 09/06/19
More insiders
Date Price Change Volume
13/06/24 41.12 -0.92% 861 497
12/06/24 41.5 +4.56% 1,280,318
11/06/24 39.69 -0.25% 857,905
10/06/24 39.79 +2.16% 897,616
07/06/24 38.95 -2.31% 665,333

Delayed Quote Nasdaq, June 13, 2024 at 09:00 pm

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
41.12 USD
Average target price
58.04 USD
Spread / Average Target
+41.14%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW